Source: International Congress 2018 – Mitochondrial dysfunction as a driver of lung disease



Rating:

Share or cite this content

Citations should be made in the following way:
A. Mora (Pittsburgh, United States of America). Lung fibrosis - a disease of mitochondrial dysfunction. International Congress 2018 – Mitochondrial dysfunction as a driver of lung disease

Member's Comments

No comment yet.

Related content which might interest you: Mitochondrial dysfunction in chronic lung disease Source: International Congress 2016 – Dysfunctional mitochondria in respiratory disease Year: 2016 Mitochondrial dysfunction in lung ageing and disease Source: Eur Respir Rev, 29 (157) 200165; 10.1183/16000617.0165-2020 Year: 2020 Possible role of liver disease and respiratory insufficiency in osteopenia in cystic fibrosis patients Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Lung function in children with cystic fibrosis liver disease Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 LATE-BREAKING ABSTRACT: Age-related PINK1 deficiency promotes mitochondria dysfuntion, epithelial injury and fibrosis in the lung Source: International Congress 2014 – Lung cell biology in injury and repair Year: 2014 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Metabolic and respiratory functioning of patients with cystic fibrosis during the years preceding death Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Cystic fibrosis lung disease assessed by lung clearance index Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013 Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Serologically assessed elastin degradation is related to force vital capacity in patients with IPF Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Pathophysiology of cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 1-13 Year: 2014 Effect of statins on endothelial dysfunction in patients with chronic obstructive pulmonary disease and metabolic syndrome Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016